
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediterr J Rheumatol</journal-id><journal-id journal-id-type="iso-abbrev">Mediterr J Rheumatol</journal-id><journal-id journal-id-type="publisher-id">MJR</journal-id><journal-title-group><journal-title>Mediterranean Journal of Rheumatology</journal-title></journal-title-group><issn pub-type="epub">2529-198X</issn><publisher><publisher-name>The Mediterranean Journal of Rheumatology (MJR)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32411928</article-id><article-id pub-id-type="pmc">7219644</article-id><article-id pub-id-type="doi">10.31138/mjr.31.1.6</article-id><article-id pub-id-type="publisher-id">MJR-31-1-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Recommendations</subject></subj-group></article-categories><title-group><article-title>Recommendations Regarding COVID19 Infection in Rheumatic Patients in Greece</article-title></title-group><contrib-group><contrib contrib-type="author"><collab>The Greek Rheumatology Society and Professional Association of Rheumatologists (ERE-EPERE)</collab></contrib></contrib-group><author-notes><corresp id="C1"><bold>Corresponding Author:</bold> Dimitrios Vassilopoulos, M.D., Professor of Medicine &#x02013; Rheumatology, 2nd Department of Medicine and Laboratory, Clinical Immunology-Rheumatology Unit, National and Kapodistrian University of Athens School of Medicine Hippokration General Hospital, 114 Vass. Sophias Ave., 115 27 Athens, Greece, Tel.: +30-213-2088516, Fax: +30-213-2088399, E-mail:<email>dvassilop@med.uoa.gr</email></corresp></author-notes><pub-date pub-type="collection"><month>3</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>31</day><month>3</month><year>2020</year></pub-date><volume>31</volume><issue>1</issue><fpage>6</fpage><lpage>7</lpage><history><date date-type="received"><day>27</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Mediterranean Journal of Rheumatology (MJR)</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This work is licensed under and Creative Commons Attribution-NonCommercial 4.0 International License.</license-p></license></permissions><kwd-group><kwd>COVID19</kwd><kwd>recommendations</kwd><kwd>rheumatic diseases</kwd><kwd>immunosuppressives</kwd><kwd>biologic agents</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>The Greek Rheumatology Society &#x00026; Professional Association of Rheumatologists (ERE-EPERE) in response to the recent COVID19 pandemic has issued the following recommendations regarding COVID19 infection in patients with rheumatic diseases.</p></sec><sec sec-type="subjects"><title>ARE PATIENTS WITH RHEUMATIC DISEASES AT INCREASED RISK FOR SEVERE DISEASE (&#x0201c;VULNERABLE POPULATION&#x0201d;)?</title><p>The majority of patients with COVID19 infection (80%) in the general population develop mild to moderate disease (including those with or without pneumonia), whereas ~14% severe (severe pneumonia with hypoxemia and lung infiltrates) and ~6% critical (respiratory failure, septic shock and/or multi-organ failure) disease.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p><p>According to the published reports so far, older age appears to be the most important risk factor for severe disease.<sup><xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref></sup> Other risk factors include cardiovascular and respiratory diseases, hypertension, diabetes mellitus and probably male sex.<sup><xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref></sup></p><p>Until today, no data are available regarding the risk for severe disease in patients with auto-immune/auto-inflammatory rheumatic diseases who are receiving or not immunosuppressive or immunomodulatory agents.<sup><xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref></sup> There has been only one report of 18 patients with history of cancer from China, which showed that their risk for developing critical disease or death was higher (39% vs. 8%) compared to the rest of the infected population (n=1.572).<sup><xref rid="B5" ref-type="bibr">5</xref></sup> However, it should be noted that these patients with history of neoplasia were older (63 vs<italic>.</italic> 49 years old) and more frequently smokers (22% vs<italic>.</italic> 7%).<sup><xref rid="B5" ref-type="bibr">5</xref></sup></p><p>It is unknown whether the lack of data for rheumatic patients is due to the low frequency of autoimmune inflammatory diseases in the general population (~2&#x02013;2.5%), especially those treated with high-potency immunosuppressives, to inadequate recording, or to an actual absence of increased risk. However, the lack of published data for these patients does not exclude the possibility that they are at higher risk for a severe outcome.</p><p>Based on the above limited data, our National Society, taking into account the critical situation with the COVID19 infection worldwide and the potential risk for severe disease in our patients:
<list list-type="alpha-upper"><list-item><p><italic>Recommends that patients with autoimmune/auto-inflammatory rheumatic diseases could be classified as being at higher risk for severe infection, based on their:</italic>
<list list-type="simple"><list-item><p>- underlying rheumatic disease (eg, vital system involvement such as: respiratory, cardiovascular, renal, hematologic, etc.)</p></list-item><list-item><p>- immunosuppressive/immunomodulatory treatment and</p></list-item><list-item><p>- specific co-morbidities (old age, hypertension, cardiovascular or respiratory diseases, diabetes mellitus)</p></list-item></list></p></list-item><list-item><p><italic>Urges Rheumatologists to state clearly in their medical reports for rheumatic patients who are still employed, their:</italic>
<list list-type="simple"><list-item><p>- type of rheumatic disease,</p></list-item><list-item><p>- immunosuppressive/immunomodulatory treatment administered,</p></list-item><list-item><p>- characterization as a &#x0201c;vulnerable group&#x0201d; (based on Recommendation A), and</p></list-item><list-item><p>- need for increased protective measures (leave of absence, change of working post, working from home, etc., depending on the nature of their employment), taking always into account their exposure risk to the virus.
</p></list-item></list>
</p></list-item></list>
</p></sec><sec sec-type="discussion"><title>WHAT IS THE IMPACT OF ANTI-RHEUMATIC THERAPIES ON THE RISK FOR SEVERE COVID19 INFECTION?</title><p>Regarding the group of patients who receive immunomodulatory or immunosuppressive therapies, particularly biologics, there are inadequate data as of today, regarding their effect on the outcome of the infection (mild/moderate <italic>vs.</italic> severe/critical).</p><p>Although the World Health Organisation (WHO),<sup><xref rid="B6" ref-type="bibr">6</xref></sup> the National Organisation of Public Health in Greece (<ext-link ext-link-type="uri" xlink:href="https://eody.gov.gr/covid-19-odigies-therapeias/">https://eody.gov.gr/covid-19-odigies-therapeias/</ext-link>) and experts in the field<sup><xref rid="B7" ref-type="bibr">7</xref></sup> do not recommend glucocorticoids (GCs) in patients with severe COVID19 infection, in a recent retrospective study from China, administration of methylprednisolone in patients with acute respiratory distress syndrome (ARDS) resulted in a significant reduction in mortality (from 62% to 46%, Hazard Ratio = 0.38).<sup><xref rid="B8" ref-type="bibr">8</xref></sup> Randomized trials currently in progress (data from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>) are expected to answer this specific question.</p><p>In addition to GCs, a number of anti-rheumatic drugs (hydroxychloroquine, tocilizumab, Intravenous Immunoglobulin) are also being tested for their potential usefulness in patients at different stages of COVID19 infection (data from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>). In a recent study, a Janus kinase inhibitor (Baricitinib) was suggested as a potential therapy based on artificial intelligence data.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p></sec><sec sec-type="subjects"><title>WHAT SHOULD PATIENTS WITH RHEUMATIC DISEASES WHO RECEIVE ANTI-RHEUMATIC TREATMENT DO?</title><p>As of today, International Rheumatology Societies<sup><xref rid="B10" ref-type="bibr">10</xref>
&#x02013;<xref rid="B12" ref-type="bibr">12</xref></sup> do not recommend discontinuation of anti-rheumatic therapies in rheumatic patients who are asymptomatic or have not been clearly exposed to infected patients.</p><p>Based on the available data, ERE-EPERE:
<list list-type="alpha-upper"><list-item><p>Does not recommend the discontinuation of immunosuppressive/immunomodulatory therapies (especially biologics) in all rheumatic patients</p><p>The decision for temporary discontinuation (per os, subcutaneous treatments), postponement (intravenous treatments) or switching (from intravenous to subcutaneous) treatment should be individualized by the treating rheumatologist based on the underlying rheumatic disease (type, severity), the type of immunosuppressive/immunomodulatory treatment, the co-morbidities (old age, hypertension, concomitant cardiovascular or respiratory problems, diabetes mellitus) and the exposure risk to the virus of the individual patient.</p></list-item><list-item><p><italic>Recommends the immediate discontinuation of immunosuppressive/immunomodulatory therapies (with the exception of GCs and hydroxychloroquine) in patients with rheumatic diseases who:</italic>
<list list-type="simple"><list-item><p>- had high risk contact (duration&#x0003e; 15 min, distance &#x0003c;2 m) with a patient with confirmed COVID19 infection, or</p></list-item><list-item><p>- have symptoms of acute respiratory infection or</p></list-item><list-item><p>- develop COVID19 infection</p></list-item></list>
</p></list-item></list>
</p><p>The above recommendations may be revised based on the emerging new data and the new guidelines issued by our National Organization of Public Health.</p></sec></body><back><sec sec-type="conflict"><title>CONFLICT OF INTEREST</title><p>The authors declare no conflict of interest.</p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><mixed-citation publication-type="web"><article-title>Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)</article-title>. Accessed at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)">https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)</ext-link> on March 20, 2020.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WH</given-names></name><name><surname>Ou</surname><given-names>CQ</given-names></name><etal/></person-group>
<article-title>Clinical Characteristics Of Coronavirus Disease 2019 In China</article-title>. <source>N Engl J Med</source>
<year>2020</year>;<month>2</month>
<day>28</day> [Epub Ahead Of Print].</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>. <source>Lancet</source>
<year>2020</year>
<volume>395</volume>(<issue>10229</issue>);<fpage>P1054</fpage>&#x02013;<lpage>62</lpage> [Epub ahead of print].</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title>. <source>Lancet Respir Med</source>
<year>2020</year>
<month>2</month>
<day>24</day> [Epub ahead of print].</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Cancer Patients In SARS-Cov-2 Infection: A Nationwide Analysis In China</article-title>. <source>Lancet Oncol</source>
<year>2020</year>;<volume>21</volume>:<fpage>335</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32066541</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="web"><article-title>WHO: Clinical Management Of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected. Interim Guidance</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/Clinical-Management-Of-Severe-Acute-Respiratory-Infection-When-Novel-Coronavirus-(Ncov)-Infection-Is-Suspected">https://www.who.int/publications-detail/Clinical-Management-Of-Severe-Acute-Respiratory-Infection-When-Novel-Coronavirus-(Ncov)-Infection-Is-Suspected</ext-link></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>CD</given-names></name><name><surname>Millar</surname><given-names>JE</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name></person-group>
<article-title>Clinical Evidence Does Not Support Corticosteroid Treatment For 2019-Ncov Lung Injury</article-title>. <source>Lancet</source>
<year>2020</year>;<volume>395</volume>:<fpage>473</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">32043983</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Risk Factors Associated With Acute Respiratory Distress Syndrome And Death In Patients With Coronavirus Disease 2019 Pneumonia In Wuhan, China</article-title>. <source>JAMA Intern Med</source>
<year>2020</year>;<month>3</month>
<day>13</day> [Epub Ahead Of Print].</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Griffin</surname><given-names>I</given-names></name><name><surname>Tucker</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Oechsle</surname><given-names>O</given-names></name><name><surname>Phelan</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Baricitinib As Potential Treatment For 2019-Ncov Acute Respiratory Disease</article-title>. <source>Lancet</source>
<year>2020</year>;<volume>395</volume>:<fpage>E30</fpage>&#x02013;<lpage>E31</lpage>.<pub-id pub-id-type="pmid">32032529</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="web"><article-title>EULAR Guidance For Patients COVID-19 Outbreak</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.eular.Org/Eular_Guidance_For_Patients_Covid19_Outbreak.Cfm">https://www.eular.Org/Eular_Guidance_For_Patients_Covid19_Outbreak.Cfm</ext-link>.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="web"><article-title>A Message from the ACR About Coronavirus Disease 2019 (COVID-19)</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.Rheumatology.org/announcements">https://www.Rheumatology.org/announcements</ext-link></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="web"><article-title>British Society for Rheumatology (BSR): Covid-19 (Coronavirus) - Update for Members</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.Rheumatology.org.uk/News-Policy/Details/Covid19-Coronavirus-Update-Members">https://www.Rheumatology.org.uk/News-Policy/Details/Covid19-Coronavirus-Update-Members</ext-link></mixed-citation></ref></ref-list></back></article>